The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease

Cameron McDonald-Hyman, James T. Muller, Michael Loschi, Govindarajan Thangavelu, Asim Saha, Sudha Kumari, Dawn K. Reichenbach, Michelle J. Smith, Guoan Zhang, Brent H. Koehn, Jiqiang Lin, Jason S. Mitchell, Brian T. Fife, Angela Panoskaltsis-Mortari, Colby J. Feser, Andrew Kemal Kirchmeier, Mark J. Osborn, Keli L. Hippen, Ameeta Kelekar, Jonathan S. SerodyLaurence A. Turka, David H Munn, Hongbo Chi, Thomas A. Neubert, Michael L. Dustin, Bruce R. Blazar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Regulatory T cells (Tregs) are critical for maintaining immune homeostasis. However, current Treg immunotherapies do not optimally treat inflammatory diseases in patients. Understanding the cellular processes that control Treg function may allow for the augmentation of therapeutic efficacy. In contrast to activated conventional T cells, in which protein kinase C-θ (PKC-θ) localizes to the contact point between T cells and antigen-presenting cells, in human and mouse Tregs, PKC-θ localizes to the opposite end of the cell in the distal pole complex (DPC). Here, using a phosphoproteomic screen, we identified the intermediate filament vimentin as a PKC-θ phospho target and show that vimentin forms a DPC superstructure on which PKC-θ accumulates. Treatment of mouse Tregs with either a clinically relevant PKC-θ inhibitor or vimentin siRNA disrupted vimentin and enhanced Treg metabolic and suppressive activity. Moreover, vimentin-disrupted mouse Tregs were significantly better than controls at suppressing alloreactive T cell priming in graft-versus-host disease (GVHD) and GVHD lethality, using a complete MHC-mismatch mouse model of acute GVHD (C57BL/6 donor into BALB/c host). Interestingly, vimentin disruption augmented the suppressor function of PKC-θ-deficient mouse Tregs. This suggests that enhanced Treg activity after PKC-θ inhibition is secondary to effects on vimentin, not just PKC-θ kinase activity inhibition. Our data demonstrate that vimentin is a key metabolic and functional controller of Treg activity and provide proof of principle that disruption of vimentin is a feasible, translationally relevant method to enhance Treg potency.

Original languageEnglish (US)
Pages (from-to)4604-4621
Number of pages18
JournalJournal of Clinical Investigation
Volume128
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Intermediate Filaments
Graft vs Host Disease
Vimentin
Regulatory T-Lymphocytes
Protein Kinase C
T-Lymphocytes
Protein C Inhibitor
Viral Tumor Antigens
Antigen-Presenting Cells
Protein Kinase Inhibitors
Immunotherapy
Small Interfering RNA
Homeostasis
Tissue Donors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

McDonald-Hyman, C., Muller, J. T., Loschi, M., Thangavelu, G., Saha, A., Kumari, S., ... Blazar, B. R. (2018). The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease. Journal of Clinical Investigation, 128(10), 4604-4621. https://doi.org/10.1172/JCI95713

The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease. / McDonald-Hyman, Cameron; Muller, James T.; Loschi, Michael; Thangavelu, Govindarajan; Saha, Asim; Kumari, Sudha; Reichenbach, Dawn K.; Smith, Michelle J.; Zhang, Guoan; Koehn, Brent H.; Lin, Jiqiang; Mitchell, Jason S.; Fife, Brian T.; Panoskaltsis-Mortari, Angela; Feser, Colby J.; Kirchmeier, Andrew Kemal; Osborn, Mark J.; Hippen, Keli L.; Kelekar, Ameeta; Serody, Jonathan S.; Turka, Laurence A.; Munn, David H; Chi, Hongbo; Neubert, Thomas A.; Dustin, Michael L.; Blazar, Bruce R.

In: Journal of Clinical Investigation, Vol. 128, No. 10, 01.10.2018, p. 4604-4621.

Research output: Contribution to journalArticle

McDonald-Hyman, C, Muller, JT, Loschi, M, Thangavelu, G, Saha, A, Kumari, S, Reichenbach, DK, Smith, MJ, Zhang, G, Koehn, BH, Lin, J, Mitchell, JS, Fife, BT, Panoskaltsis-Mortari, A, Feser, CJ, Kirchmeier, AK, Osborn, MJ, Hippen, KL, Kelekar, A, Serody, JS, Turka, LA, Munn, DH, Chi, H, Neubert, TA, Dustin, ML & Blazar, BR 2018, 'The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease', Journal of Clinical Investigation, vol. 128, no. 10, pp. 4604-4621. https://doi.org/10.1172/JCI95713
McDonald-Hyman, Cameron ; Muller, James T. ; Loschi, Michael ; Thangavelu, Govindarajan ; Saha, Asim ; Kumari, Sudha ; Reichenbach, Dawn K. ; Smith, Michelle J. ; Zhang, Guoan ; Koehn, Brent H. ; Lin, Jiqiang ; Mitchell, Jason S. ; Fife, Brian T. ; Panoskaltsis-Mortari, Angela ; Feser, Colby J. ; Kirchmeier, Andrew Kemal ; Osborn, Mark J. ; Hippen, Keli L. ; Kelekar, Ameeta ; Serody, Jonathan S. ; Turka, Laurence A. ; Munn, David H ; Chi, Hongbo ; Neubert, Thomas A. ; Dustin, Michael L. ; Blazar, Bruce R. / The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease. In: Journal of Clinical Investigation. 2018 ; Vol. 128, No. 10. pp. 4604-4621.
@article{9c2ecf1502a8477494536b9d7203b790,
title = "The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease",
abstract = "Regulatory T cells (Tregs) are critical for maintaining immune homeostasis. However, current Treg immunotherapies do not optimally treat inflammatory diseases in patients. Understanding the cellular processes that control Treg function may allow for the augmentation of therapeutic efficacy. In contrast to activated conventional T cells, in which protein kinase C-θ (PKC-θ) localizes to the contact point between T cells and antigen-presenting cells, in human and mouse Tregs, PKC-θ localizes to the opposite end of the cell in the distal pole complex (DPC). Here, using a phosphoproteomic screen, we identified the intermediate filament vimentin as a PKC-θ phospho target and show that vimentin forms a DPC superstructure on which PKC-θ accumulates. Treatment of mouse Tregs with either a clinically relevant PKC-θ inhibitor or vimentin siRNA disrupted vimentin and enhanced Treg metabolic and suppressive activity. Moreover, vimentin-disrupted mouse Tregs were significantly better than controls at suppressing alloreactive T cell priming in graft-versus-host disease (GVHD) and GVHD lethality, using a complete MHC-mismatch mouse model of acute GVHD (C57BL/6 donor into BALB/c host). Interestingly, vimentin disruption augmented the suppressor function of PKC-θ-deficient mouse Tregs. This suggests that enhanced Treg activity after PKC-θ inhibition is secondary to effects on vimentin, not just PKC-θ kinase activity inhibition. Our data demonstrate that vimentin is a key metabolic and functional controller of Treg activity and provide proof of principle that disruption of vimentin is a feasible, translationally relevant method to enhance Treg potency.",
author = "Cameron McDonald-Hyman and Muller, {James T.} and Michael Loschi and Govindarajan Thangavelu and Asim Saha and Sudha Kumari and Reichenbach, {Dawn K.} and Smith, {Michelle J.} and Guoan Zhang and Koehn, {Brent H.} and Jiqiang Lin and Mitchell, {Jason S.} and Fife, {Brian T.} and Angela Panoskaltsis-Mortari and Feser, {Colby J.} and Kirchmeier, {Andrew Kemal} and Osborn, {Mark J.} and Hippen, {Keli L.} and Ameeta Kelekar and Serody, {Jonathan S.} and Turka, {Laurence A.} and Munn, {David H} and Hongbo Chi and Neubert, {Thomas A.} and Dustin, {Michael L.} and Blazar, {Bruce R.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1172/JCI95713",
language = "English (US)",
volume = "128",
pages = "4604--4621",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease

AU - McDonald-Hyman, Cameron

AU - Muller, James T.

AU - Loschi, Michael

AU - Thangavelu, Govindarajan

AU - Saha, Asim

AU - Kumari, Sudha

AU - Reichenbach, Dawn K.

AU - Smith, Michelle J.

AU - Zhang, Guoan

AU - Koehn, Brent H.

AU - Lin, Jiqiang

AU - Mitchell, Jason S.

AU - Fife, Brian T.

AU - Panoskaltsis-Mortari, Angela

AU - Feser, Colby J.

AU - Kirchmeier, Andrew Kemal

AU - Osborn, Mark J.

AU - Hippen, Keli L.

AU - Kelekar, Ameeta

AU - Serody, Jonathan S.

AU - Turka, Laurence A.

AU - Munn, David H

AU - Chi, Hongbo

AU - Neubert, Thomas A.

AU - Dustin, Michael L.

AU - Blazar, Bruce R.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Regulatory T cells (Tregs) are critical for maintaining immune homeostasis. However, current Treg immunotherapies do not optimally treat inflammatory diseases in patients. Understanding the cellular processes that control Treg function may allow for the augmentation of therapeutic efficacy. In contrast to activated conventional T cells, in which protein kinase C-θ (PKC-θ) localizes to the contact point between T cells and antigen-presenting cells, in human and mouse Tregs, PKC-θ localizes to the opposite end of the cell in the distal pole complex (DPC). Here, using a phosphoproteomic screen, we identified the intermediate filament vimentin as a PKC-θ phospho target and show that vimentin forms a DPC superstructure on which PKC-θ accumulates. Treatment of mouse Tregs with either a clinically relevant PKC-θ inhibitor or vimentin siRNA disrupted vimentin and enhanced Treg metabolic and suppressive activity. Moreover, vimentin-disrupted mouse Tregs were significantly better than controls at suppressing alloreactive T cell priming in graft-versus-host disease (GVHD) and GVHD lethality, using a complete MHC-mismatch mouse model of acute GVHD (C57BL/6 donor into BALB/c host). Interestingly, vimentin disruption augmented the suppressor function of PKC-θ-deficient mouse Tregs. This suggests that enhanced Treg activity after PKC-θ inhibition is secondary to effects on vimentin, not just PKC-θ kinase activity inhibition. Our data demonstrate that vimentin is a key metabolic and functional controller of Treg activity and provide proof of principle that disruption of vimentin is a feasible, translationally relevant method to enhance Treg potency.

AB - Regulatory T cells (Tregs) are critical for maintaining immune homeostasis. However, current Treg immunotherapies do not optimally treat inflammatory diseases in patients. Understanding the cellular processes that control Treg function may allow for the augmentation of therapeutic efficacy. In contrast to activated conventional T cells, in which protein kinase C-θ (PKC-θ) localizes to the contact point between T cells and antigen-presenting cells, in human and mouse Tregs, PKC-θ localizes to the opposite end of the cell in the distal pole complex (DPC). Here, using a phosphoproteomic screen, we identified the intermediate filament vimentin as a PKC-θ phospho target and show that vimentin forms a DPC superstructure on which PKC-θ accumulates. Treatment of mouse Tregs with either a clinically relevant PKC-θ inhibitor or vimentin siRNA disrupted vimentin and enhanced Treg metabolic and suppressive activity. Moreover, vimentin-disrupted mouse Tregs were significantly better than controls at suppressing alloreactive T cell priming in graft-versus-host disease (GVHD) and GVHD lethality, using a complete MHC-mismatch mouse model of acute GVHD (C57BL/6 donor into BALB/c host). Interestingly, vimentin disruption augmented the suppressor function of PKC-θ-deficient mouse Tregs. This suggests that enhanced Treg activity after PKC-θ inhibition is secondary to effects on vimentin, not just PKC-θ kinase activity inhibition. Our data demonstrate that vimentin is a key metabolic and functional controller of Treg activity and provide proof of principle that disruption of vimentin is a feasible, translationally relevant method to enhance Treg potency.

UR - http://www.scopus.com/inward/record.url?scp=85054464989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054464989&partnerID=8YFLogxK

U2 - 10.1172/JCI95713

DO - 10.1172/JCI95713

M3 - Article

C2 - 30106752

AN - SCOPUS:85054464989

VL - 128

SP - 4604

EP - 4621

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 10

ER -